GULD J, BENTZON M W, BLEIKER M A, GRIEP W A, MAGNUSSON M, WAALER H
Bull World Health Organ. 1958;19(5):845-951.
A new batch of PPD tuberculin, RT 23, prepared at the request of UNICEF by the Statens Seruminstitut, Copenhagen, has been compared with previous batches of tuberculin from the Statens Seruminstitut and with the International Standard for the Purified Protein Derivative of Mammalian Tuberculin. The comparisons were made by intradermal tuberculin testing. The majority of tests were carried out in human subjects with various types and levels of tuberculin sensitivity-namely, tuberculous patients in the Netherlands; BCG-vaccinated as well as spontaneously tuberculin-sensitive army recruits in the Netherlands; BCG-vaccinated schoolchildren in Denmark; population groups in the tropics (Mauritius and Nigeria) including a high proportion of persons with low-grade sensitivity. In addition, comparisons were made in guinea-pigs sensitized in different ways.For these comparisons, RT 23 was diluted both with phosphate-buffered saline alone (as were the other preparations) and with phosphate-buffered saline containing 0.05 per thousand Tween 80 as a stabilizing agent.The results were found to differe significantly with the type and level of sensitivity of the groups tested. Thus, while the potency ratio of RT 23 and the International Standard is about 2:1 in BCG-vaccinated persons, it is about 1:1 in persons with naturally acquired tuberculin sensitivity. RT 23 in diluent containing Tween 80 elicited larger reactions than did RT 23 in ordinary diluent; however, when reactions of the same size were compared, a difference in character was observed: the reactions to RT 23 diluted with Tween 80 were softer and less frequently bullous.On the basis of the results-in terms of reaction size-obtained in patients and in non-vaccinated recruits, it is suggested that one unit of RT 23 should be defined as 0.02 mug of the dry substance; for use as a first or single dose in routine testing, 0.02 mug of RT 23 in diluent stabilized with Tween 80, or 0.06 mug in diluent without Tween 80, is recommended.
应联合国儿童基金会的要求,哥本哈根国家血清研究所制备了一批新的PPD结核菌素RT 23,并将其与该研究所之前的几批结核菌素以及哺乳动物结核菌素纯化蛋白衍生物国际标准品进行了比较。比较是通过皮内结核菌素试验进行的。大多数试验在具有不同类型和水平结核菌素敏感性的人体受试者中进行,即荷兰的结核病患者;荷兰接种卡介苗以及自然结核菌素敏感的新兵;丹麦接种卡介苗的学童;热带地区(毛里求斯和尼日利亚)的人群,其中包括很大比例低敏感性的人。此外,还对以不同方式致敏的豚鼠进行了比较。对于这些比较,RT 23既用单独的磷酸盐缓冲盐水(其他制剂也是如此)稀释,也用含有千分之0.05吐温80作为稳定剂的磷酸盐缓冲盐水稀释。结果发现,根据受试组的敏感性类型和水平不同而有显著差异。因此,虽然在接种卡介苗的人中RT 23与国际标准品的效价比约为2:1,但在自然获得结核菌素敏感性的人中约为1:1。含吐温80稀释剂中的RT 23比普通稀释剂中的RT 23引起的反应更大;然而,当比较相同大小的反应时,观察到了性质上的差异:用吐温80稀释的RT 23引起的反应更轻微,水疱形成频率更低。根据在患者和未接种新兵中获得的反应大小结果,建议将1个单位的RT 23定义为0.02微克干物质;在常规检测中用作首次或单次剂量时,建议使用含吐温80稳定剂的稀释剂中0.02微克的RT 23,或不含吐温80稀释剂中0.06微克的RT 23。